Nachrichten und Videos - JP MORGAN CHASE & CO.

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire SAN FRANCISCO, Jan. 28, 2025 Over 230 Italian and U.S. executives, Italian government leaders, and investors attended the eighth edition of "Italy On the Move" Seven life sciences executives provided business insights during "Navigating Transatlantic Partnerships in Life Sciences"...

TORONTO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- J. P. Morgan Asset Management (JPMAM)* today announced the final January 2025 cash distributions for the below listed JPMorgan ETFs. The JPMorgan ETFs trade on the Toronto Stock Exchange (TSX). Unitholders of record on February 3, 2025 will receive cash distributions payable on February 7, 2025. Details of the “per unit” distributions are as follows: JPMorgan ETF name Ticker symbol Distribution per unit ($) Payment frequency JPMorgan US Equity...

Financial giant JPMorgan has set up a "war room" to keep up with President Trump's policy changes after he began his second ......

Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference PR Newswire NEW YORK, Jan. 17, 2025 NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in minimally invasive Microwave Ablation (MWA) technology, was present in San Francisco amid the 2025 J.P. Morgan Healthcare Conference, one of the most prominent healthcare investment gatherings globally. Following its successful...

Hugel vows to become global leader at J.P. Morgan Healthcare Conference PR Newswire SAN FRANCISCO, Jan. 16, 2025 - Hugel CFO Eva Huang presents mid- to long-term growth strategy at the APAC Track - The medical aesthetics company aims to expand its presence in more than 80 toxin markets, 70 dermal filler markets, and more than 10 cosmetics markets by 2028 SAN FRANCISCO , Jan. 16, 2025 /PRNewswire/ -- Hugel Inc., a leading global medical aesthetics company, announced its key achievements in 2024...

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 Advancing into new stage of sustainable growth and global innovation SAN FRANCISCO and SUZHOU, China , Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

Erik Joly van ABN AMRO Private Banking zegt dat vierde kwartaal het beste in jaren kan worden....

Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire INCHEON, South Korea, Jan. 14, 2025 Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 Company reinforces its commitment to a two-pillar growth strategy focusing on its groundbreaking new drug developments including...

Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference PR Newswire INCHEON, South Korea, Jan. 14, 2025 - The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON, South Korea , Jan. 14, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and...

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy PR Newswire NEW HAVEN, Conn., Jan. 13, 2025 Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the MoDE TM...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:45 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com . The webcast...

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced it will participate at the upcoming J.P. Morgan Healthcare Conference in San Francisco, California. Management will give a presentation on Tuesday, January 14, 2024, at 7:30 AM Pacific Time. A webcast of the presentation will be available on P3’s Investor Relations Website at https://ir.p3hp.org/ . A replay will be available on...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43 rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 15,...

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 13, 2025 Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow...

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 13, 2025 – PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treatment of adults with RRP – – Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started...

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 SOUTH SAN FRANCISCO, Calif. , Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate...

Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire BURLINGTON, N.C., Jan. 10, 2025 BURLINGTON, N.C. , Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14 , at 3:45 p.m. (PT). A live audio webcast of the fireside chat will be available via the Company Investor...

Areteia Therapeutics, Inc. (« Areteia »), une société de biotechnologie au stade clinique qui développe de nouvelles thérapies d'inflammation et d'immunologie, en se focalisant en premier lieu sur l'asthme éosinophile sévère, a annoncé aujourd'hui que la société allait faire un exposé lors de la 43 e conférence annuelle sur les soins médicaux de J.P. Morgan, le mardi 14 janvier 2025 à 13 h 30 (heure de Pacifique) à San Francisco, en Californie. Une copie de la présentation sera...

Hengdian Group Capital and Apeloa Pharmaceutical to participate in 2025 J.P. Morgan Healthcare Conference PR Newswire HANGZHOU, China, Jan. 9, 2025 HANGZHOU, China , Jan. 9, 2025 /PRNewswire/ -- Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025 . HgC CEO Gary Xu and Apeloa VP George Cai will be present along with their teams to connect with industry...

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 9, 2025 GERMANTOWN, Md. , Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00...